Clinical Trial Update: A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating tucatinib with trastuzumab and mFOLFOX6 versus standard-of-care in first-line HER2-positive metastatic colorectal cancer; recr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Neoplasms

Drugs mentioned

• MFOLFOX6
• Trastuzumab (trastuzumab)
• Tucatinib (tucatinib)

Snippet

Sponsor: Seagen, a wholly owned subsidiary of Pfizer | Conditions: Colorectal Neoplasms | Phase 3 | Status: RECRUITING